|
Factor VII-activating protease (FSAP) has the ability to activate coagulation factor VII (independent of tissue factor) and pro-urokinase. Thus, FSAP holds a key position in the delicate balance between blood clot formation and degradation. A mutant form of FSAP, called the "Marburg I variant", has a reduced ability to activate pro-urokinase, but has retained its potential to activate factor VII. This leads to an imbalance of the coagulation (blood clotting) system toward a pro-coagulatory state, a condition that could increase the risk of thrombotic events and therefore the potential to develop blood clots.
The study of factor VII-activating protease is especially important to the clinical diagnostic industry because of its potential for the use in identifying individuals at risk of developing cardiovascular disease. (FSAP fact sheet)
To view a summary of the available scientific information about FSAP, please click here.
American Diagnostica has licensed from Dade Behring world-wide rights for distinct in vitro diagnostic tests for FSAP and rights to sell reagents to the research community (Press Release).
The range of products comprises:
-mAbs against FSAP and
-mAbs against FSAP Marburg I variant.
-ELISA for the quantitative determination of FSAP
-ELISA for the determination of the FSAP Marburg I variant
|
